Excessive active pharmaceutical ingredients in substandard and falsified drugs should also raise concerns in low-income countries
Bibliographic Data
| ID | 19552160 |
|---|---|
| Authors | Elisa M Maffioli (0000-0003-3303-7945, University of Michigan), Marie C Montás (Harvard Global Health Institute), Chimezie Anyakora (0000-0002-7872-1380, Pan-Atlantic University) |
| Year | 2024 |
| Volume | 14 |
| Pages | 03029-03029 |
| Publication date | 2024-06-07 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Journal of Global Health (JOURNAL) |
| Journal identifiers | ISSN: 2047-2978 • E-ISSN: 2047-2986 |
| Publisher | International Society of Global Health (PUBLISHER • GB) |
| DOI | 10.7189/jogh.14.03029 |
| PMID | 38843042 |
| OpenAlex | W4399390834 |
| Language | EN |
| References cited | 17 |
Substandard and falsified (SF) medicines still do not receive enough attention in public health. Substandard medicines are authorised medical products that fail to meet their quality standards or specifications, or both, due to within-factory errors or degradation in supply chains. Falsified medicines, instead, are defined as deliberately and fraudulently misrepresenting medicines’ identity, composition, or source [...]
Active ingredient · Business · Environmental health · Intellectual Property and Patents · Medicine · Pharmaceutical Economics and Policy · Pharmaceutical Quality and Counterfeiting · Pharmacology
| Citation velocity | historical |
|---|---|
| Highly cited | No |